NASDAQ:APLT - Applied Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $63.50
  • Forecasted Upside: 190.09 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$21.89
▲ +0.1 (0.46%)
1 month | 3 months | 12 months
Get New Applied Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$63.50
▲ +190.09% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Applied Therapeutics in the last 3 months. The average price target is $63.50, with a high forecast of $85.00 and a low forecast of $44.00. The average price target represents a 190.09% upside from the last price of $21.89.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Applied Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/17/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2020BarclaysLower Price Target$64.00 ➝ $44.00Low
i
10/8/2020TruistInitiated CoverageBuy$85.00 ➝ $85.00Low
i
6/17/2020CowenReiterated RatingBuyMedium
i
Rating by Marc Frahm at Cowen Inc
4/22/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00Medium
i
3/3/2020CowenReiterated RatingBuyN/A
i
Rating by Marc Frahm at Cowen Inc
2/27/2020BarclaysInitiated CoverageOverweight$64.00 ➝ $64.00Low
i
1/27/2020UBS GroupBoost Price TargetBuy$65.00Medium
i
1/9/2020CitigroupBoost Price TargetBuy$29.00 ➝ $44.00High
i
1/8/2020CowenReiterated RatingBuyHigh
i
1/8/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$24.00 ➝ $43.00High
i
6/10/2019CitigroupInitiated CoverageBuy$29.00High
i
6/10/2019CowenInitiated CoverageOutperformHigh
i
6/10/2019UBS GroupInitiated CoverageBuyHigh
i
6/10/2019Robert W. BairdInitiated CoverageOutperform$24.00High
i
(Data available from 1/17/2016 forward)
Applied Therapeutics logo
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $21.89
$21.25
$22.95

50 Day Range

MA: $22.36
$19.91
$24.15

52 Week Range

Now: $21.89
$13.58
$57.39

Volume

95,585 shs

Average Volume

100,722 shs

Market Capitalization

$492.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Applied Therapeutics?

The following equities research analysts have issued reports on Applied Therapeutics in the last twelve months: Barclays PLC, Cowen Inc, The Goldman Sachs Group, Inc., Truist, UBS Group AG, and Zacks Investment Research.

What is the current price target for Applied Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Applied Therapeutics in the last year. Their average twelve-month price target is $63.50, suggesting a possible upside of 190.1%. Truist has the highest price target set, predicting APLT will reach $85.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $44.00 for Applied Therapeutics in the next year.

What is the current consensus analyst rating for Applied Therapeutics?

Applied Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLT will outperform the market and that investors should add to their positions of Applied Therapeutics.

What other companies compete with Applied Therapeutics?

How do I contact Applied Therapeutics' investor relations team?

Applied Therapeutics' physical mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company's listed phone number is 212-220-9226 and its investor relations email address is maeve@argotpartners.com. The official website for Applied Therapeutics is www.appliedtherapeutics.com.